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Alcohol consumption is correlated positively with risk for breast cancer in observational studies, but 
observational studies are subject to reverse causation and confounding. The association with 
epithelial ovarian cancer (EOC) is unclear. We performed both observational Cox-regression and 
two-sample Mendelian randomization (MR) analyses using data from various European cohort 
studies (observational) and publicly available cancer consortia (MR). These estimates were 
compared with World Cancer Research Fund (WCRF) findings. In our observational analyses, the 
multivariable-adjusted hazard ratios (HR) for a one standard drink/day increase was 1.06 (95% 
confidence interval; 1.04,1.08) for breast cancer and 1.00 (0.92,1.08) for EOC, both of which were 
consistent with previous WCRF findings. MR ORs per genetically predicted one standard drink/day 
increase estimated via 34 SNPs using MR-PRESSO were 1.00 (0.93,1.08) for breast cancer and 0.95 
(0.85,1.06) for EOC. Stratification by EOC subtype or estrogen receptor status in breast cancers made 
no meaningful difference to the results. For breast cancer, the confidence intervals for the 
genetically derived estimates include the point-estimate from observational studies so are not 
inconsistent with a small increase in risk. Our data provide additional evidence that alcohol intake is 











The World Cancer Research Fund (WCRF) concluded that alcohol intake is a probable cause of breast 
cancer, with an estimated additional risk of 9% per 10g/day increase in consumption of ethanol, but 
that there is inadequate evidence to evaluate the association with epithelial ovarian cancer (EOC) 1,2. 
It is, however, difficult to measure any effect of elevated alcohol consumption from conventional 
observational data because of the possible confounding issues: alcohol consumption is itself 
associated with many other lifestyle and socio-economic factors, which may themselves be a risk 
factor for cancers and are difficult to quantify. Estimates from observational studies may additionally 
be biased by other mechanisms 3, including recall bias due to differences in the completeness of the 
subjective indications of alcohol consumption across case-control status, selection bias 4,5 against 
heavy users of alcohol due to the preferential participation of reasonable healthy individuals and 
reverse causality. The WCRF estimates are based on data from population-based prospective cohort 
studies, where exposure information is collected before the event of interest occurs. Although cohort 
studies in general are less likely to suffer from bias, it is still impossible to rule out confounding. Also, 
such studies typically only measure exposure variables once or a few times, precluding detailed 
individual modelling of exposures over time 6. In principle, double blinded randomized trials are the 
best way to evaluate causality, but such studies are usually logistically cumbersome and may be 
unethical.  
 
A Mendelian randomization (MR) study, using genetic variants associated with alcohol consumption 
as an instrument for alcohol consumption, offers a way to test hypotheses of causality, since the 
genetic variants are less likely to be associated with other known or unknown confounders, and they 
are not influenced by (pre-)clinical stages of the diseases 7. Conceptually, MR relies on the random 
assortment of genetic variants during meiosis to mimic a “natural” randomized trial 8. However, for 
MR estimates to make valid inferences on causality, several assumptions have to be met 8. Typically, 
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such a genetic instrument only explains a fraction of the variance of the exposure variable, and 
therefore MR studies need very large numbers of participants to answer questions of causality. For 
alcohol consumption, previous MR studies have used the rs1229984 variant (as this SNP is associated 
with high levels of acetaldehyde and facial flushing 9) as a genetic instrument to evaluate the link 
between alcohol intake and disease outcomes 10–12. Two-sample mendelian randomization is an 
extension of the traditional MR methodology that leverages greater statistical power for MR analyses 
by utilizing independent summary-based datasets to derive the genetic association on alcohol and 
cancer outcome separately without the need for individual level data. As larger GWAS have identified 
more risk loci and GWAS of outcomes of interest have increased in size, power has recently become 
adequate to support meaningful statistical inference 13.   
Using several large independent population-based prospective cohorts, we first tested whether 
alcohol intake is associated with risk of breast cancer and EOC via observational analyses, to compare 
against previous WCRF findings. We then evaluated whether there is genetic evidence to support a 
causal relationship between the two using a two-sample Mendelian randomization study approach 
utilizing consortia data from both the Breast Cancer Association Consortium (BCAC) and Ovarian 
Cancer Association Consortium (OCAC) for breast and ovarian cancer, respectively. Both observational 
and genetically derived estimates were then used to infer whether there is evidence for a causal 
relationship between alcohol intake and these cancers. 
 
Materials and Methods   
Overview 
For the large-scale population-based cohorts, we evaluated the observational association between 
self-reported alcohol consumption and risk of breast and ovarian cancer via Cox-regression analyses. 
Study-specific hazard ratio (HR) estimates were then combined via a fixed-effect meta-analysis 
(separately for each cancer). For the genetic causality analyses, we performed a two-sample MR to 
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assess whether genetically predicted alcohol consumption is associated with breast/ovarian cancer 
susceptibility using publicly available consortia data. Instruments for the MR analyses were obtained 
from an alcohol consumption GWAS performed on the UK Biobank white British participants.  
 
 
Description of observational cohort studies 
Data from Copenhagen General Population Study (CGPS) and Copenhagen City Heart Study (CCHS) 
The CGPS14 and the CCHS15 are two large prospective general population studies from Denmark. For 
both studies, residents from Copenhagen were invited to complete a baseline questionnaire and 
undergo a physical examination. The questionnaire includes the number of alcoholic drinks consumed 
daily and this was used to derive standard drinks per week (for this study 1 standard drink ~ 12g 
ethanol). Blood samples were also obtained. In total, 69 420 women participated, 60 205 from the 
CGPS (enrolled between 2003 to 2015) and the remaining 9 215 from the CCHS (enrolled during four 
examinations from 1976-78, 1981-83, 1991-94, and 2001-03). A total of 2 312 incident breast cancer 
and 327 EOC cases were identified. Women with diagnosis of breast cancer prior to examination or 
who had missing information on covariates were excluded from the analysis. All participants gave 
written informed consent, and both CCHS and CGPS were approved by the Danish ethics committees 
(H-KF01‐144/01 and KF100.2039/91). Full details on the observational HR analysis in the CGPS and 
CCHS are provided in Supplementary Methods. 
 
Data from the Karolinska Mammography Project for Risk Prediction of Breast Cancer (KARMA). 
The KARMA study is a large Swedish breast cancer prospective cohort study comprising 70 877 women 
who attend regular mammographic screening across four hospitals in Sweden 16. The aim of the 
project is to identify risk factors for breast cancer such as mammographic density, genetic and lifestyle 
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factors. Information on tumour characteristics, such as ER status, was identified through registers. 
Self-reported alcohol intake (in grams) estimated via questionnaires was standardised into number of 
standard drinks/week using a nominal conversion scale of 10g/standard drink.  For our HR analysis, 
we identified 985 incident breast cancer cases in a cohort of 60 903 women with non-missing data on 
confounders. We did not perform the analysis for EOC due to the limited number of cases (n=57). See 
Supplementary Methods for a complete description. 
 
Data from the UK Biobank cohort 
The UK Biobank (UKB) cohort consists of 502 000 middle-aged individuals recruited from across the 
United Kingdom 17. The UKB study was approved by the North West Multi-Centre Research Ethics 
Committee (reference number 06/MRE09/65), participants at the time of recruitment gave informed 
consent to participate in UK Biobank and be followed up, using a signature capture device. 487 910 
individuals passed initial genetic quality control protocols. We identified 215 830 women genetically 
similar to those of white-British ancestry through ancestral principal component techniques 18. The 
UKB records extensive (n>2 000) phenotypes including anthropometric traits, disease status and 
lifestyle behaviours. Number of standard drinks per day (one standard drink in the UKBB is roughly 
equivalent to 12g/day of alcohol) was calculated as a weighted sum of daily consumption on various 
types of alcoholic beverages (Supplementary methods; see also Supplementary Table 1 and 2). Non-
drinkers were given a score of zero standard drinks per day. Information about cancer diagnosis 
among the UKB participants was obtained through data-linkage between self-report, hospital records 
and cancer registries. Individual cancer types were defined based on ICD-10 definitions, as per 
previous work 19. After excluding women with a history of cancer (excluding non-melanoma skin 
cancer) prior to enrolment including recurrent cancer cases, the cohort comprised 141 071 white 
British women with 4,068 women diagnosed with breast cancer and 425 with EOC. However, the 
proportion of individuals with missing data on the necessary covariates (e.g. menopausal status, 
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education attainment, nulliparity) were relatively high (i.e. only 1 771 breast cancer cases and 187 
EOC cases had complete data). Cox regression was used to obtain hazard ratios for cancer risk per 
standard drinks/day increase in alcohol consumption. A complete description of the observational HR 
analysis for alcohol and cancer in the UKB is provided in Supplementary Methods.  
 
Meta-analysis of observational findings  
We then performed an observational meta-analysis of the association estimates combining the UKB 
results with those obtained from the CCHS+CGPS and KARMA study for breast cancer and EOC. All 
association estimates were scaled to reflect a one standard drink per day increase (an increase of 
~10g/day of ethanol) to facilitate comparison with our MR findings. Estimates were combined under 
a fixed-effect inverse variance weighted model using the rmeta R library. These results were then 
compared against the existing WCRF findings on both cancers 1,2. 
 
Genetic analyses 
In this two-sample MR study, we derived instrumental variables for alcohol consumption from the UK 
Biobank cohort. We then evaluated whether these alcohol-associated instruments were associated 
with breast/ovarian cancer risk using GWAS summary statistics obtained from the Breast Cancer 
Association Consortium (BCAC) and the Ovarian Cancer Association Consortium (OCAC). A flowchart 
illustrating the complete MR procedure is shown in Figure 1. 
(Figure 1 here) 
Breast and ovarian cancer risk GWAS 
The BCAC breast cancer GWAS summary statistics 20, derived from a total of 122 977 cases and 105 
974 controls of European ancestries, were obtained from a publicly available repository 
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(http://bcac.ccge.medschl.cam.ac.uk/bcacdata/oncoarray). Among these, 69 501 of the cases were 
identified to have ER+ breast cancer, and 21 468 breast cancer cases were ER-. Participants in the 
BCAC were recruited from various case-control and cohort studies around the world. BCAC 
participants involved in the breast cancer GWAS were genotyped via one of these genotyping 
platforms: (i) custom Illumina iSelect genotyping arrays, (ii) OncoArray or (iii) the iCOGS array. 
Genotypes were then imputed against the 1000 Genomes Project Phase III reference panels using 
IMPUTE2 21. A full description of the genetic quality control procedures is given elsewhere 20. The 
association between SNPs and cancer outcome were estimated using conventional multiple logistic 
regression adjusting for top ancestral principal components and age 20.  
 
The OCAC EOC GWAS summary statistics 22, derived from a total of 22 406  cases and 40 941 controls 
of European ancestries, were obtained from a publicly available repository 
(http://ocac.ccge.medschl.cam.ac.uk/). The genotyping platforms used were broadly similar to those 
used in the BCAC breast cancer GWAS. Top ancestral principal components were fitted as covariates 
in both the breast cancer and EOC GWAS model to account for the presence of population 
substructure. Prior to our main analyses, we excluded SNPs that were poorly imputed (INFO<0.6) or 
had very low minor allele frequencies (MAF<0.01) for both GWAS datasets. Similarly, the association 
between SNPs and cancer outcome were estimated using conventional multiple logistic regression 
adjusting for top ancestral principal components and age 22. 
 
Deriving genetic instruments for alcohol consumption (UKB data) 
The complete description of how estimated standard drinks per week was derived via self-reported 
consumption of alcoholic beverages is provided in Supplementary Methods. In brief, we computed 
the participants’ total alcohol standard drinks per week using both frequency and quantity of alcohol 
consumption, summing across the alcohol content (in std drinks) from self-reported quantities of 
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various types of alcoholic beverage consumed weekly. Non-drinkers are included in the GWAS, and 
assigned a score of zero standard drinks per week.  We performed a GWAS on standard alcoholic 
drinks per week to calibrate genetic instruments that are predictive of self-reported alcohol 
consumption among white British women in the UKB. We used the software BOLT-LMM 23, a Bayesian 
linear mixed model GWAS framework to explicitly model the genetic relatedness within the sample. 
Genetic sex, age and 10 ancestral principal components were included as covariates. We performed 2 
separate GWAS: using i) the estimated alcohol quantity in both sexes (n=432 178) and ii) the estimated 
alcohol quantity in females only (n=197 948). For each alcohol GWAS result, only SNPs that were 
genome-wide significant and had MAF>0.01 were retained. Clumping on the SNPs were then 
performed based on LD (𝑟2 <0.01) and maximum distance of 1 000 kb apart to ensure that selected 
instruments are strictly independent. We identified 72 instruments (including SNP rs1229984) from 
the combined-sex drinks/week GWAS (Supplementary Table 3). The combined-sex GWAS was used to 
robustly identify alcohol associated SNPs but in our main MR analysis we adopted SNP effect sizes 
estimated among females only. In order to ensure that our analyses were protected against weak 
instrument bias, we only used 34 out of 72 SNPs that were successfully replicated in the female-only 
alcohol GWAS (p<1e-5 in females).  
   
Two-sample Mendelian randomization 
GWAS summary statistics were used to obtain association estimates for genetic predictors of alcohol 
on cancer outcomes (breast or ovarian cancer) from the respective consortia (BCAC and OCAC). The 
estimated statistical power to detect MR associations at various effect sizes (ORs) is shown in 
Supplementary Table 4. We extracted the SNP-cancer association estimates and minor allele 
frequency information for each of the 34 alcohol-associated SNP instruments. We fitted a 
multiplicative random effect inverse variance weighted (IVW) model to obtain a combined estimate 
of the causal effect inferred via multiple SNPs 24. For each test, palindromic SNPs with strands that 
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could not be inferred via allele frequency were excluded. The global Cochran Q statistics was first 
evaluated to determine MR findings with heterogeneous effect sizes. For tests with strong evidence 
of causal effect heterogeneity, we then repeated our IVW MR analyses by manually filtering out SNPs 
that showed strong evidence for having heterogenous effect estimates, defined by SNPs with a 
Cochran’ Q statistics exceeding 3.84. The heterogeneity-adjusted MR estimate will be reported in the 
main results section for traits that have inflated global Cochran Q statistics (p-heterogeneity < 0.05). 
 
Previous studies have shown that SNPs associated with alcohol intake might be pleiotropically linked 
with changes in adiposity, or simply markers for smoking behaviour or education attainment, some of 
which might confound the association with these cancers. Discarding SNPs on the basis of a pleiotropic 
association might result in loss of power if the association is linked through the same causal pathway 
(vertical pleiotropy). However, determining the modes of pleiotropy for each SNP instrument is not a 
trivial task. Instead, we applied a multivariable MR (MVMR) model to evaluate the direct effect 
between genetically predicted alcohol intake on breast/ovarian cancer by regressing out the genetic 
effect of these variants on BMI, BMI-adjusted waist-to-hip ratio, education attainment and cigarettes 
smoked per day. The marginal OR for alcohol intake (drink/day) on cancer risk(s) after adjusting for 
the aforementioned risk factors were reported. Curation of the phenotypes used in the MVMR 
framework is described in Supplementary Methods.   
 
We scaled our MR estimate to reflect a genetically predicted one drink/day increase in alcohol 
consumption (by multiplying the predicted change in log(OR) of cancer for 1 standard drink/week by 
7). All statistical analyses (including MR sensitivity analyses) were performed in statistical package R 






Observational. We assessed evidence for a non-linear relationship between alcohol and breast cancer 
or EOC outcomes by evaluating the dose-response relationship over strata of increasing alcohol intake 
in the observational analyses. For the KARMA study (where ER status was available for breast cancer 
cases), we performed stratified analyses to evaluate whether the alcohol-breast cancer association 
differed by ER status. There is no information available for ER-status in both the UK Biobank and 
Copenhagen cohort studies. Due to the high rate of missingness in the covariate data in our UKB 
(multivariable adjusted) observational HR analyses, we finally performed missing data imputation to 
evaluate whether the associations varied with more recovered samples (see Supplementary 
Methods).   
 
MR analyses For the genetically derived estimates, we first attempt to re-evaluate our MR findings 
using only the rs1229984 SNP as an instrument fitted through a Wald-type estimator 26. Next we 
ensure that our findings were not biased by violation of the MR assumptions by repeating our analyses 
using the following alternative MR models: MR Egger regression 27, weighted median 28 and the 
penalised weighted median model29. Deviations of the MR Egger regression intercept from the null for 
each tested outcome were used to assess evidence of directional pleiotropy. The multi-SNP MR 
analyses were also repeated using the MR-PRESSO technique 30 which provides adjusted causal 
estimates after filtering out heterogeneous SNP-outliers. MR estimates derived using these models 
were reported alongside the main (IVW) MR results to ensure robustness of findings as different 
techniques relax different assumptions. Funnel plots and leave-one-out MR plots were also generated 
to evaluate whether the causal estimates were driven by strong outliers. We also performed a SNP-
lookup on the recently published alcohol drinks/week GWAS summary data to evaluate whether our 
instrument-alcohol associations replicate well in the much larger GSCAN alcohol GWAS 31. Detailed 
descriptions of the MR sensitivity analyses are provided in the Supplementary Methods.  
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For the MR analysis on breast cancer, we additionally performed stratified analyses based on estrogen 
receptor (ER) status, whilst for EOC, we subsequently evaluated the association of alcohol across 
different histotypes including the most common HGSOC histotype.  
 
Results 
Conventional observational analyses on alcohol consumption 
Observational association between alcohol consumption with breast and ovarian cancer risk 
Breast cancer. Alcohol consumption was associated with increased risk of breast cancer in the 
CCHS+CGPS cohorts with a HR of 1.09 per standard drink/day (95% C.I. 1.05, 1.13), and the Swedish 
KARMA study with HR 1.07 (0.97,1.19) while the HR in the UKB dataset was lower (HR 1.04 (1.01, 
1.07)). Meta-analysing all these estimates yielded an HR of 1.06 (1.04,1.08) for risk of breast cancer 
per one standard drink/day (Figure 2 upper panel) 
Ovarian cancer. In the UK Biobank, higher alcohol consumption was associated with a reduction in risk 
for cancers in the ovary with an age-adjusted HR of 0.92 (0.85,0.99). Using the multivariable adjusted 
model (N=61,267, N=187 cases), the log(HR) was unchanged, albeit with wider confidence intervals 
(adjusted HR 0.92 (0.83,1.03)) due to missing information on covariates. In CCHS+CGPS, the estimated 
HR (HR=1.07 (0.96,1.20)) was in the opposite direction, but with 95% CIs that overlapped the estimates 
from the UKBB. Combining both these estimates yielded an meta-analysed HR of 1.00 (0.92,1.08) for 
the risk of EOC per one standard drink of 10 g alcohol per day increase in alcohol consumption (Figure 
2 lower panel). 
(Figure 2 here) 
Instrumental variable analyses - Genetically predicted alcohol consumption 
Association of genetically predicted alcohol consumption with breast cancer and EOC 
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(Figure 3 here) 
For a one unit increase in genetically predicted daily alcohol intake (using 34 variants), the odds ratio 
on breast cancer was 1.03(0.93,1.14) in standard IVW analysis, with a tighter confidence interval when 
MR-PRESSO was used to discard one heterogeneous SNPs (OR 1.00 [0.93,1.08], figure 3). For EOC, the 
point estimate was less than one, although with relatively wide confidence intervals (OR 0.89 
(0.73,1.08)). The MR-PRESSO MR OR estimate for EOC was attenuated slightly towards the null (OR 
0.95 [0.85,1.06]). Given that all but one of the SNPs (rs62055546) used in our genetic instrument 
appeared homogeneous in our MR-PRESSO analysis we adopted the MR-PRESSO results as our 
primary results. Estimates of the MR association under alternative models are shown together in 
Figure 3. The comparison of our genetically derived estimate against our new observational findings 
and the WCRF results for breast cancer and EOC risk is provided in Figure 4. The original results not 
manually filtered for heterogenous SNPs are shown in Supplementary Table 11.  
 
For the multivariable analyses, the estimated marginal OR on breast cancer for one drinks/week 
increase is 1.03 (0.97,1.10) in the MVMR model after excluding SNPs with high heterogeneity scores 
(Q>3.84), showing no evidence of effect size attenuation in the univariate MR model due to negative 
pleiotropy. The MVMR OR estimate for ovarian cancer was 0.97 (0.87,1.09), see Supplementary Table 
12.  
(Figure 4 here) 
Sensitivity analyses 
The observational HR association between alcohol and breast cancer and EOC for different levels of 
alcohol consumption indicated no strong evidence for a non-linear relationship (Supplementary Table 
5-6). There was limited evidence that the alcohol-breast cancer association differed by ER status in 
the KARMA study (Supplementary Table 7). Furthermore, the age-adjusted and fully-adjusted models 
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gave similar estimates suggesting minimal evidence for confounding on the factors that were 
controlled for (Supplementary Table 8). To address the high rate of missingness in the UK Biobank 
multivariable-adjusted HR analyses, multiple imputation was performed to recover missing 
information in the covariates. We first verified that missingness of our covariates of interests can be 
predicted by our set of auxiliary variables and other covariates (satisfying the MAR assumption for 
accurate imputation) (see Supplementary Methods 8; Supplementary Figure 5 and 6). We generated 
a total of five sets of imputation datasets and pooled the estimates from each individual imputed 
dataset. The pooled regression estimates from imputed data revealed minor attenuation of the 
estimate between alcohol drinks/day and both cancers (HR on breast cancer =1.02 [1.00, 1.03] ; 
ovarian cancer = 0.94 [0.90, 0.99]) towards the null, providing more precise estimates upon modelling 
the covariates that previously had high rates of missingness adequately. However, these revised 
estimates were not meaningfully different from the original multivariable HR estimates as shown by 
the overlapping confidence intervals (Supplementary Table 9).  
(Figure 5 here) 
The confidence interval of the estimate from our single SNP MR analyses using the rs1229984 (ADH1B) 
variant (strongest instrument, explaining 0.23% of variation in alcohol intake, p=1e-128) largely 
overlaps those of the multi-instrument MR results (Supplementary Figure 1). The MR scatter plots for 
both cancers using the original 34 alcohol SNP instruments are shown in Figure 5. The F-statistics for 
our instruments suggest that each of our 34 SNPs are strong instruments, with SNP-alcohol 
associations (female only) being replicated successfully in the subsequent GSCAN GWAS revealing 
limited evidence for weak instrument bias (Supplementary Table 13-14). Our Steiger Z-test 
(Supplementary Table 15) also indicated no evidence for instrument mis-specification (i.e. our SNP 
instrument r^2 on alcohol >> r^2 on outcome) in our study design. Estimates derived from alternative 
MR methods (before/after filtering heterogenous instruments) reveal that our findings were robust 
against weak violation of MR assumption, with the MR-Egger intercepts showing no evidence for 
16 
 
directional pleiotropy (Supplementary Table 10, 11, 15 and 16). In our pleiotropy assessment, we did 
not observe evidence for an association between our genetic instruments with potential confounders 
including age at menarche, oral contraceptive use, smoking quantity, coffee consumption and 
psychiatric traits, except for BMI in the UKB (See Supplementary Table 17 and 18). However, the 
magnitude of association between rs1229984 and BMI is so small that it is very unlikely to have 
substantially biased our estimates. Moreover, our MR-PRESSO findings were statistically consistent 
with the IVW estimates for each trait. The distribution of effect sizes around the null across multiple 
sensitivity MR analyses provide strong support for an overall null or a very weak positive relationship 
between alcohol and breast cancer or EOC.    
 
In our exploratory MR analyses, stratification by ER status produced essentially unchanged the MR 
results for breast cancer (Supplementary Table 19). Similarly, for subtypes of EOC, results were 
indistinguishable from those for overall EOC: the high-grade serous estimate was 0.95 [0.85,1.06] 
(Supplementary Figure 2). 
 
Discussion 
In this study, we evaluated the association between alcohol consumption and breast and ovarian 
cancer using conventional observational prospective designs and MR approaches. The point estimates 
for breast cancer from the observational findings were slightly higher than those from MR, but with 
overlapping confidence intervals. Although the confidence intervals are wider for the MR estimates, 
the MR design is likely to be robust to some of the issues which can hamper interpretation of 
observational studies, such as confounding. Taken together, although our MR estimate overlaps the 
null, the confidence interval from our MR estimate remains consistent with a modest increase as 
consistently reported in observational findings. For EOC, the effect appears null in both the 




Comparison with previous literature 
Earlier molecular investigations found that alcohol may be implicated in the development of breast 
cancer, especially ER+ breast cancer, as it modulates estrogen levels. This adverse influence of alcohol 
is supported by a study investigating the link between alcohol intake and percentage of breast density 
(PBD), postulating a potential relationship between alcohol intake and breast cancer susceptibility via 
increased PBD 32. Similarly, many observational findings have found that alcohol consumption is 
associated with risk of breast cancers 33–36. Results from a large meta-analysis of  27 cohort studies 
showed that even light drinking (<1 drink/day) is associated with increased risk of breast cancer in 
women 37. In our study, we found suggestive evidence from our observational study meta-analysis 
that increased alcohol consumption is associated with susceptibility for breast cancers, although the 
magnitude of association was slightly lower than those reported by the WCRF 2. Here we add MR 
analysis to provide additional evidence as to whether the association seen in the observational studies 
represents a true causal association. Whilst the MR estimates had confidence intervals overlapping 
those from the observational studies, the most likely causal effect was zero (point estimate from MR 
analysis), with the relatively narrow MR confidence intervals suggesting the causal effect of alcohol 
intake is at most very small. 
 
The null association between alcohol and EOC was previously shown in the study by Kelemen et al. 38 
pooling together data from 12 case-control studies in OCAC, , and in other pooled case-control39 and 
cohort40 studies. In contrast, Cook et al.41 showed that self-reported wine consumption was associated 
with a reduction in EOC risk in a recent Canadian study. One possible explanation for such an 
association is that the relationship may have been driven by residual confounding with other 
exposures correlated with socio-economic factors such as educational attainment 38,41. While the 
estimated direction of effect for alcohol and ovarian cancer differed (non-significantly) for the UKB 
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and Copenhagen cohorts, it is difficult to draw any definitive statement given the overlapping CIs and 
low number of cases. In our observational meta-analyses, we did not find strong evidence to support 
a protective association between alcohol and overall EOC, consistent with the WCRF findings 1. Our 
MR results for EOC were concordant with the observational study results. 
 
Strength and limitations 
Our large sample size combining data from various sources allow us to assess the role of alcohol 
consumption on breast/ovarian cancer with reasonably good precision. The MR approach provides 
additional evidence to triangulate evidence for causality. Our additional MR analysis using alcohol 
consumption instruments calibrated only among European women helps protect against biased 
inferences due to weak instruments 42. While these SNPs combined explain only a small amount 
(~0.92%) of variation in alcohol consumption among women (Supplementary Table 3), due to the large 
sample sizes from both OCAC and BCAC, the confidence intervals on our MR estimates are reasonably 
precise. The use of a larger set of SNP instruments also enabled better assessment of potential bias in 
MR findings through the use of alternative MR models which allow inference under a range of different 
assumptions (heterogeneity of effect sizes, horizontal pleiotropy).   
 
This study had some limitations. While genetically derived estimates are unlikely to be affected by 
confounding, the magnitude of association between these genetic instruments and estimated 
standard drinks detected in GWAS analyses relies on the accuracy of self-reported data, which may 
contain self-report bias. This might also apply to the UKBB with known healthy volunteer bias43, in 
which the genetic instruments were derived. In recent years, investigators have used multi-instrument 
MR experiments due to availability of genetic data on large cohorts. The multi-instrument approach 
is expected to minimise the standard errors around the causal estimates (relative to just a single SNP), 
although in practice we only found this to be the case when one heterogeneous SNP was discarded 
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using MR-PRESSO (Figure 3). Furthermore, the strength of our instruments (explaining ~1% of 
variance) remain insufficient to detect small ORs and make further inference on causality, evident 
from the large degree of overlap in CIs between the observational and MR estimates. The presence of 
weak instruments in the multi-instrument MR can potentially bias the overall causal estimates 
towards the null 42, however this is unlikely the case given that our instruments satisfy the strong 
instrument criteria (median F-stat 22.2; Interquartile range: 19.5 - 30.3) and most of our variants show 
evidence of replication in the recent combined-sex drinks/week GWAS from GSCAN 31. Of the 98 
associations reported in the GSCAN alcohol GWAS meta-analysis31, 95 replicated in our combined-sex 
alcohol GWAS in UKBB alone, suggesting that the genotype-alcohol associations used in this study are 
fairly stable. Results from alternative MR estimators that are robust against horizontal pleiotropy were 
similar to the IVW findings, although the confidence intervals were wider for those techniques. In 
contrast, assessing the rs1229984-only estimate remains informative because rs1229984 by itself is 
by far the strongest and most extensively studied instrument among the SNP set with well-studied 
biological insights to justify its association with alcohol consumption. Apart from the ADH1B variant, 
the biological pathways linking the SNP instruments with alcohol consumption are not well 
understood; for a trait like alcohol, unmeasured pleiotropy remains a concern as variants might 
consequently influence alcohol intake through changes in socio-economic status, cultural factors and 
other social behaviours. In our assessment for bias, the MR-Egger intercept for alcohol-EOC did not 
show any evidence of directional pleiotropy affecting our MR findings (Supplementary Table 16).  
 
Earlier studies have suggested a link between acetaldehyde (ADH) and cancer cell growth 44,45, but it 
is unclear whether these associations were mainly driven by a change in alcohol consumption. 
Disentangling the complex effects of the rs1229984 variant is difficult, as previous studies have shown 
that the variant is associated with esophageal carcinoma 46, potentially due to accumulation of 
acetaldehyde among minor allele carriers although our single SNP MR analyses using the rs1229984 
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(ADH1B) variant find weak evidence for an association with breast cancer risk. Our PheWAS findings 
on rs1229984 found no strong evidence that the ADH1B instrument was associated with potential risk 
factors linked with breast or ovarian cancer that are unlikely to be mediated through increased alcohol 
consumption (Supplementary Table 17). However, we cannot exclude the possibility of rs1229984 
being associated with other factors related to carcinogenesis and unmeasured confounders. We are 
unable to assess whether our MR causal inference remain consistent when we conservatively 
excluded rs1229984 from the main analyses, as it resulted in wide confidence intervals on the estimate 
(rs1229984 being the instrument that explains the highest amount of genetic variance, Supplementary 
Table 3).   
 
For our observational analyses, selection bias might be present for the study cohorts if participants 
are more healthy than non-participants. Our reliance of self-reported consumption data for the 
observational analyses is vulnerable to recall error, and the definition of standard drinks may differ 
slightly across regions, contributing to higher heterogeneity in our exposures. In the covariate-
adjusted model, the power to detect meaningful associations were hindered by a large degree of 
missingness on information for the covariates, especially the UK Biobank cohort where the number of 
cancer events from the multivariable-adjusted analyses were essentially halved.  Our multiple 
imputation analyses recovered valuable information on both smoking pack/years and duration of 
hormone-replacement therapy and in the pooled regression estimate adjusted for these covariates in 
the imputed dataset there was a small degree of attenuation of the effect size between alcohol and 
both cancers (towards the null). Whilst the regression analysis on the imputed dataset characterises 
confounding better, the estimates based on imputed data (with twice the number of events) were not 
meaningfully different to the original multivariable adjusted findings for the UKB (Supplementary 




When we compare the observational findings across different cohorts, the breast cancer estimates for 
one standard drink/day increase from the Copenhagen cohorts and KARMA were broadly consistent 
with the overwhelming evidence from previous studies. However the estimated HR from the UKB 
cohort is slightly lower (HR 1.04). This might be explained by the healthy-volunteer selection bias in 
the recruitment for the UKB cohort, resulting in under-estimation of the true effect size. Conversely, 
genetic estimates are conceivably less affected by these biases, but they can be vulnerable to biases 
in the presence of horizontal pleiotropy. We performed sensitivity analyses based on filtering out SNPs 
with heterogeneous causal effects to reduce the chances of horizontal pleiotropy biasing the estimate 
including the use of MVMR to adjust for confounding risk factors, although in practice this made no 
meaningful changes to our results. If participants in the genetic study under-reported their true 
alcohol consumption this may lead to an underestimate of the SNP-alcohol effect sizes, resulting in an 
inflated estimate from the MR analysis. If the SNP-alcohol effect sizes were underestimated, it would 
suggest more strongly that alcohol intake is not causally associated with breast cancer. Finally, our risk 
estimates from the observational and MR analyses were on similar but not identical scales (i.e. OR 
versus HR); however for low prevalence outcomes any discrepancy is likely to be small. Individuals 
with high alcohol consumption are less likely to participate in the studies included, and competing 
risks after study participation may have influenced our estimates of the effect of risk factor on 
outcome, but since the observational studies largely reproduced results from other observational 
studies, this bias is likely to have been small. 
 
The MR estimates for alcohol and risk of breast cancer or EOC remain valid under the assumption that 
alcohol consumption and log(OR) of these disease outcomes have a linear relationship. This is a strong 
assumption, given previous speculation about a J-shaped relationship between alcohol and other 
disease outcomes (e.g. cardiovascular diseases) where abstainers are at higher risk similar to those 
drinking more than moderate amounts 47,48. Despite our inability to perform MR-by-stratum 
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(evaluating effect of genetically predicted alcohol consumption on risk of disease at various 
consumption levels) due to insufficient sample size, our observational findings show little evidence 
that the relationship between alcohol intake and these cancers is non-linear. Given that the alcohol 
variants (such as rs1229984) might predict both drinker status and quantity consumed, modelling the 
MR association within drinkers-only might potentially induce collider bias 49.  
 
Taken together, Mendelian randomization analyses are not inconsistent with findings from several 
cohort studies showing that moderate alcohol consumption is associated with a modest increase in 
risk of breast cancer (upper 95% CI of OR on breast cancer being 1.10 for a genetically predicted 1 
drink per day increase). For EOC alcohol intake is unlikely to have anything other than a very small 
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Figure 1. Schematic diagram illustrating the Mendelian randomization (MR) framework for the 
main analysis.  
 
Figure 2 Meta-analysis of the observational hazard ratio estimates for daily alcohol consumption 
on breast and ovarian cancer. Estimates were adjusted for BMI, oral contraceptive use, nulliparity, 
physical activity and education attainment. Please refer to supplementary table 7 for the estimated 
HR adjusted for age only. There is no strong evidence for effect heterogeneity (p>0.1) among 
estimates from each of these studies.  
 
Figure 3. Mendelian randomization estimates for the relationship between alcohol consumption 
and risk of breast/ovarian cancers. The confidence interval around the estimates narrowed down 
after we removed SNPs via the outlier test in MR-PRESSO. 
 
Figure 4. Comparison of observational and genetic (MR) estimates for the association between 
standard drink per day with breast and ovarian cancer risk.  Observational HR estimates were 
obtained via fixed effect meta-analysis of the studies used in the main analysis. The MR-PRESSO 
outlier-adjusted estimates were reported here as the MR-analysis findings. 
 
Figure 5. Scatter plot for the genetic association between alcohol drinks/week SNP instruments 
and risk of breast and ovarian cancers. The slope of the fitted line in the scatter plots reflect the MR 
causal estimates for each type of MR estimator. The scatter plot shows the association of a 
genetically predicted one standard drinks/week increase on log(OR) of the outcome (cancer) risk 
inferred via each alcohol SNP instrument. The panel (A) refers to the plot for overall EOC; (B) refers 
to the plot for the risk of overall breast. For both plots, the right-most point refers to the rs1229984 
SNP estimate. The forest plot for the individual SNP estimates along with the leave-one-SNP-out MR 
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Supplementary materials and methods 
Method 1. Estimating phenotypic variance tagged by genetic variants 
 
For a set of 𝑘 SNP instruments and phenotype of interest 𝑌, we used the following equation to estimate 
the total phenotypic variance explained by instruments: 
𝑟2 = ∑  
𝑘
𝑖=1
 2𝑝𝑖(1 − 𝑝𝑖)𝛽𝑖
2 /𝑉𝑎𝑟(𝑌) 
 
Where 𝑝𝑖  and 𝛽𝑖 refers to the minor allele frequency and the magnitude of association of the i-th SNP. 
 
Method 2. Deriving number of alcoholic standard drinks in UK Biobank 
Information on quantity and frequency of alcohol consumption, was obtained through self-report 
questionnaires in the UKB. Frequency of consumption (AC-Frequency) was assessed in 501,718 
participants (UKB field IDs: 1558) with the item “About how often do you drink alcohol?”. Frequency was 
originally assessed at a scale ranging from 1 (daily or almost daily) to 6 (never), but was recoded so that 
a lower score represented less frequent drinking. For individuals who reported multiple instances (via 
multiple visits) of alcohol intake, only the first assessment was used.  
In those who drank at least once or twice a week, information on quantity of consumption (AC-Quantity) 
was assessed (n=348,039). AC-Quantity was assessed based on the average weekly alcohol intake for 
five general classes: red wine (1568), champagne plus white wine (1578), spirits (1598), beer plus cider 
(1558), and fortified wine (1608). The following item was used: “In an average WEEK, how many servings 
of {class of alcohol} would you drink?”. To combine the different classes of alcohol, we followed the 
procedures developed by Clarke et al. (2)  with some minor changes, as discussed below. To calculate 
the total number of alcohol standard drinks, the number of reported drinks was multiplied with a 
conversion factor depending on the class of alcohol (Supplementary Table 1). For the less-frequent 
drinkers, we repeated the same procedure using equivalent assessments available for their monthly 
(instead of weekly) quantity. These values were converted to weekly units by dividing by 4.3 (~30 
days/7). The average value for total drinks/day was then calculated for each frequency category (see 
Supplementary Table 2). We subsequently identified outliers as those who had a score that deviated >5 
SD from the average in each female drinker category.  
 
We then imputed the missing values with the sex-specific average of total standard drinks/week for 
each of the 6 frequency categories. This allowed us to utilise data from the maximum number of female 
participants for the GWAS analyses, further improving the statistical power to detect robust genetic 
instruments for alcohol intake. Finally, we selected only individuals of white-British ancestry based on 
clustering via ancestral principal components and performed the GWAS analyses as per description in 
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the main text. Unlike Clarke et al. (2), we did not include weight (in kg) as a covariate in the GWAS 
model. 
Method 3. Observational data for the Copenhagen General Population Study and the Copenhagen City 
Heart Study 
 
We performed cox regression analyses of the 69,420 women to evaluate the relationship between daily 
number of standard alcohol drinks of 10 g alcohol per day on breast cancer risk or ovarian cancer risk, 
adjusted for cohort, age, parity, use of contraceptives, hormone therapy, daily and cumulative tobacco 
use, height, weight, BMI, nulliparity and menopausal status. Follow up began at date of examination, 
and ended at next examination, date of first breast or ovarian cancer diagnosis, date of death, or end of 
follow up (December 31st 2016), whichever came first. Each woman from CCHS could contribute with up 
to 4 observations, depending on the number of examinations of that woman. Recurrent events were not 
considered. Women with event prior to entry were excluded from that particular analysis. Analyses 
were performed using STATA 13.1 SE.  
Method 4. Observational data for the Karolinska Mammography Project for Risk Prediction of Breast 
Cancer (KARMA). 
In the KARMA study, alcohol drinking behaviour of the participants was captured through diet 
questionnaires, along with information on other breast cancer related risk factors (Parity, age at 
menarche, anthropometric traits, smoking and menopausal status). Self-reported alcohol intake (in 
grams) estimated via questionnaires was standardised into number of standard drinks/week using a 
nominal conversion scale of 10g/standard drink. All individuals diagnosed with breast/ovarian cancer 
prior to recruitment were excluded. In total, 60,903 women (985 incident breast cancer cases) with non-
missing data on confounders were used for the KARMA observational analyses. Among the 985 cases, 
867 were ER+ while the remaining 118 were ER-. We derived both a crude estimate adjusting for only 
age, and a multivariable-adjusted estimate accounting for parity, age at menarche, BMI, height, hip 
circumference, smoking and menopausal status. The Software SAS v9.4 was used for the KARMA 
observational analyses. 
Method 5. Modelling the association between alcohol and BrCa/OvCa in UK Biobank  
Using our derived alcohol intake phenotype (estimated standard drinks per week), we used Cox 
proportional hazards models to quantify the association between alcohol consumption and 
breast/ovarian cancer risk. All cancers diagnosed prior to recruitment (prevalent cases) were excluded, 
retaining only 427 ovarian cancer and 4,081 breast cancer incident cases (cohort size, n=145,089 
women) all of which are filtered to be genetically unrelated. The crude model adjusts for only top 10 
ancestral principal components, with age at last follow-up as the underlying time variable. The adjusted 
model (complete_model) additionally included the following covariates: number of live births, cigarette 
pack years, smoking status (former, current, non-smoker), coffee intake, education attainment, BMI, 
height, physical activity, age at menarche and menopausal status. Individuals that are cryptically related 
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were removed by filtering individual-pairs (and retaining only one of each) with a strong degree of 
genetic relatedness (?̂? > 0.2) estimated through genetic data. The sample size for the adjusted model 
were lower due to missing data on some of the covariables (See Supplementary Table 7). The Cox 
proportional hazard models were implemented using Surv() in R. 
Method 6. Sensitivity analyses for the Mendelian randomization study 
 
Weak violation of the MR assumptions (such as SNP-confounding and invalid instruments) can severely 
bias MR inferences. To address these issues, we performed sensitivity analyses using alternative MR 
models (MR Egger, Weighted median, MR-PRESSO) that are least affected by these violations. The MR-
Egger intercepts were computed to evaluate evidence of directional pleiotropy, which would be 
captured by a non-zero intercept estimate. To generate a reliable causal estimate, we attempted to 
screen for heterogeneity in MR causal estimates through the global and individual SNP heterogeneity 
Cochran Q test (Supplementary Table 10). We conservatively excluded any SNPs with a Q-score greater 
than 3.84 (3). These estimates are provided in Supplementary Table 11. In the main text, we included 
the MR-PRESSO estimates alongside the IVW estimate to provide an estimate of the MR association that 
are robust against SNP-heterogeneity. Furthermore, leave-one-out MR analyses (MR estimates leaving 
out one SNP at a time) were also used to detect outliers in our MR estimates. For the single instrument 
(rs1229984) MR analyses, the causal estimate was computed using a wald-type ratio estimator. We 
further performed a phenome-wide association scan (PheWAS) on the rs1229984 SNP, which is the 
strongest alcohol-associated genetic variant against publicly available GWAS datasets to assess potential 
pleiotropic association with known confounders. The Steiger-Z test was also used to perform MR 
directionality test to ensure SNP instruments are acting on the correct hypothesized causal pathway and 
avoid instrument mis-specification.   
 
For the MR-PRESSO analysis, each trait (cancer outcomes) was performed using the mr_presso() function 
in the mr-presso R package (4), with default setting at Nb=5000 iterations, enabled distortion test, enabled 
outlier test and applied an outlier-significance threshold of 0.05. SNP alleles were harmonized prior to 
running these analyses via the harmonize() feature in the MR-Base R-package. All sensitivity analyses apart 
from the MR-PRESSO tests were performed using the MendelianRandomization and MR-Base R package 
(5,6). 
 
Method 7. Multivariable Mendelian randomization analyses 
 
When the exposure of interest is correlated with various other risk factors, MR estimates can be 
severely biased by horizontal pleiotropy. However, some of the SNP association on these risk factors 
might manifest in the same causal pathway, where manual removal of these variants would reduce 
statistical power for MR. The multivariable MR model can hence be used to evaluate the direct effect 
between our exposure of interest on the outcome while adjusting the genetic effect our SNPs exert on a 
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set of risk factors. This is implemented through the mv_multiple() function curated within the 
TwoSampleMR R package. The risk factors that we adjusted for includes BMI, BMI-adjusted waist-to-hip 
ratio (WHR), education attainment and cigarette smoked per day, all of which had data available in the 
UK Biobank cohort. We performed the GWAS for BMI and WHR using identical procedure to those 
described in previous work (Gharahkhani et al. 2019). We recoded education attainment as an ordinary 
variable, with the lowest score reflecting lowest attained academic qualification, with individuals that 
reported to have “Other professional qualification” excluded from the GWAS analysis. The variable is 
then ranked-transformed to allow effect size to be interpreted in changes in SD units. For cigarette per 
day, we excluded individuals reported to have smoked more than 99 cigarettes per day but retained 
individuals that reported zero consumption levels. For both education attainment and cigarette/day, the 
GWAS was performed on 438,609 white British individuals in the UK Biobank using the BOLT-LMM 
software, adjusting for recruitment age, sex and top 10 ancestral principal components. The effect 
estimate of the alcohol instruments on these risk factors obtained directly from the GWAS summary 
statistics were then applied into the MVMR model.  
 
Method 8. Imputation of missing covariate data in UK Biobank observational analyses 
In our primary cox-regression analyses, participants with missing information on any of the covariates 
are removed from the analyses. For the UK Biobank cohort, this eventually resulted in a much lower 
sample size (cases were essentially halved) for the multifactor-adjusted cox regression analyses. To be 
able to include additional samples, we imputed missing confounders via multiple imputation analyses in 
R. We extracted a collection of phenotypes on socio-economic status, sexual development, and female 
sex-specific risk factors (see list below). The pairwise correlation between these phenotypes and the 
covariates (for imputation) are shown in Supplementary Figure 5.  
 
Finalised Variables considered in the multiple imputation analyses including auxiliary variables (AX):  
“Ever smoked”, “Age at menarche”, “Duration of daily moderate physical activity”, “Duration of daily 
vigorous physical activity”, “coffee cups/day”, “drink temperature (AX) ”, “Townsend deprivation index”, 
“Duration of hormone replacement therapy (HRT)”, “Ever had HRT”, “Menopausal status”, “Smoking 
pack years”, “Overall health rating (AX)”, “Body mass index”, “Frequency of visit from friends and family 
(AX)”, “Number of live births”, “Age at first sexual intercourse (AX)”, “Renting or privately owns an 
apartment (AX)”, “Academic qualifications”, “Age completed full time education (AX)”, “Number of 
medications (AX)”, “Number of vehicles in the household (AX)”, “Birth weight (AX)”, “Height” 
 
Before we can proceed to impute the missing values on the covariates, we first extracted a series of 
auxiliary variables from the UK Biobank to assess whether missingness on any of these covariate of 
interests can be predicted by these auxiliary variables (along with the other covariates with low 
missingness). This can be done via performing a logistic regression fitting all auxiliary variables against 
the missingness status of the covariate (i.e.  we defined a ‘missingness status’ phenotype where we 
recoded missing values as 1, and non-missing values as 0 for the trait under assessment). We performed 
this check for each covariate we intend to impute, to help assess plausibility of the Missing-at-random 
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(MAR) assumption prior to multiple imputation. In our dataset, the missingness for each of our covariate 
of interests can be predicted by atleast one auxiliary variable (average predictors ~ 3), hence there is 
strong evidence to support the MAR assumption on the pattern of missingness for these covariates. We 
also compared these predictability estimates against those from the predictor matrix derived from the 
MiCE initiation process (accessible via imp$predictorMatrix upon executing 
“imp=mice(dat,m=1,max_iter=0,..))”. The comparison of the predictability of each covariate and the 
specific models used for the imputation of the trait is summarized in Table M8. We did NOT impute our 
outcome (cancer diagnosis) and exposure (alcohol drinks/week) phenotype to prevent bias from circular 
associations – these variables were manually omitted from the multiple imputation process. 
 
The missing data imputation was performed using mice() from the MiCE R package for missing data 
imputation (available at https://github.com/stefvanbuuren/mice). The process was set for a maximum 
of 5 iterations, generating 5 distinct datasets with pseudo-random seed set at seed=123. We applied 
different imputation models to impute covariate data of varying characteristics: the predictive mean 
matching model (pmm) for quantitative trait, logistic regression (logreg) for binary trait, proportional 
odds model (plr) for ordered categorical traits and polytomous regression (polyreg) for 
ordered/unordered categorical traits. Cox proportional hazard estimates from the 5 distinct imputed 
datasets were then computed using Surv() and then pooled together via the pool() function in MiCE. The 
pooled estimates were finally compared against the original estimate (multivariable adjusted Cox-
model) for both cancers to evaluate potential difference in observational findings. Note that the 
multiple imputation analysis was performed on the entire set of UK Biobank female participants used in 





















































  UKB 
cohort 
Duration 
  of Hormone 
replacement 
therapy 
Continuous 0.732 0.713 Yes 3 6 pmm N/A 
Cigarettes 
  smoked in pack 
years 
Continuous 0.361 0.352 Yes 12 5 pmm N/A 
Qualification Categorical 
  (ordered) 
0.172 0.167 Yes 13 8 polr Yes 
Coffee 
  consumption 
(cup/day) 
Continuous 0.073 0.071 Yes 1 2 pmm Yes 
Duration 





0.055 0.054 Yes 3 1 polr Yes 
Duration 




0.051 0.049 Yes 3 2 polr Yes 
Age 
  at menarche 
Continuous 0.029 0.028 Yes 1 1 pmm Yes 
Ever 
  smoked 
Binary 0.003 0.003 Yes 3 3 logreg Yes 
BMI Continuous 0.003 0.002 Yes 11 3 pmm Yes 
Height Continuous 0.002 0.002 Yes 7 2 pmm Yes 
Menopausal 
  status 
Categorical 
  (unordered) 
0.002 0.001 Yes 7 3 polyreg Yes 
Number 
  of live births 
Continuous 0.001 0.001 Yes 8 4 pmm Yes 
Townsend 
  deprivation 
index 
Continuous 0.001 0.001 Yes 0 0 pmm Yes 
Participant 
  ID 
N/A 0 0 N/A N/A N/A N/A Reference 
only 
Sex N/A 0 0 N/A N/A N/A N/A N/A 
  
The model “pmm” refers to the predictive mean matching model for quantitative traits, “polr” refers to proportional odds 
model for ordered categorical variable(s), “polyreg” refers to polytomous logistic regression for unordered categorical 
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variable(s) and “logreg” refers to logistic regression for binary coded variable(s). The performance of the logistic regression on 
missingness is poor (since ncases [missing=1] for traits with very low missingness is very small) apart from duration of HRT and 
cigarette smoked in pack years; note that these estimates are indicative of plausibility for MAR assumption only, since the 





































Supplementary Table 1. Conversion table for various alcoholic beverage into units of standard drinks. 
Type of alcoholic beverage UKB-ID for 
weekly; monthly 
Standard drinks equivalence 
Red wine 1568 ; 4407 1.67 
White wine 1578 ; 4418 1.67 
Fortitude wine 1608 ; 4451 2.25 
Spirits 1598 ; 4440 1 
Pint of beer 1588 ; 4429 2.3 
Other alcoholic drinks 5364 ; 4462 1.1 
 
Supplementary Table 2. Estimated average of total standard drinks per week across each consumption 
category among women in the UK Biobank cohort. 
Alcohol frequency category Description Average no. of standard 
drinks/week 
Category 1 Daily or almost daily 12.5 
Category 2 3 or 4 times a week 8.0 
Category 3 Once or twice a week 5.0 
Category 4 1 or 3 times a month 0.8 
Category 5 Special occasion only 0.5 
Category 6 Never 0 
Total - 9.4 
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Supplementary Table 3. Phenotypic variance (weekly alcohol intake) explained by alcohol-associated 
SNP instruments used in MR analysis. The variance explained by instrument (𝒓𝟐) was estimated using 
the formula provided in Supplementary methods. BETA refer to the magnitude of association on 
estimated standard drinks/week per effect allele (EA) of the SNP. EAF is the frequency of the effect 
allele. The variance for drinks/week was estimated to be 256.67 (across both sexes) and 114.60 (in 
females). Only SNPs with P<1e-5 in the female-only GWAS are used as instruments for the MR analyses. 
 
SNP CHR EA NEA Estimated across both sexes Estimated in females only 
EAF BETA P-value r^2 EAF BETA P-value r^2  
rs1229984 4 T C 0.02 -3.421 1.10E-218 0.0020 0.02 -2.471 6.80E-121 0.0023 
rs1260326 2 T C 0.39 -0.529 3.50E-58 0.0005 0.39 -0.315 4.60E-23 0.0004 
rs11940694 4 A G 0.39 -0.518 9.70E-55 0.0005 0.39 -0.342 1.40E-26 0.0005 
rs13107325 4 C T 0.93 0.706 4.50E-30 0.0003 0.93 0.300 6.70E-07 0.0001 
rs1302808 4 C A 0.80 -0.446 1.90E-27 0.0002 0.80 -0.318 6.50E-16 0.0003 
rs62055546 17 A C 0.78 0.401 1.50E-24 0.0002 0.78 0.258 1.10E-11 0.0002 
rs1004787 2 G A 0.47 -0.310 9.90E-22 0.0002 0.47 -0.235 1.10E-13 0.0002 
rs11604680 11 A G 0.68 0.305 5.50E-19 0.0002 0.68 0.167 5.80E-07 0.0001 
rs56094641 16 A G 0.60 0.251 2.30E-14 0.0001 0.60 0.072 2.20E-02 0.0000 
rs61873510 10 G T 0.67 0.263 5.70E-14 0.0001 0.67 0.181 5.80E-08 0.0001 
rs9822731 3 T C 0.78 -0.288 7.80E-14 0.0001 0.78 -0.189 2.40E-07 0.0001 
rs485425 11 C G 0.45 -0.229 5.30E-13 0.0001 0.45 -0.141 3.40E-06 0.0001 
rs4630328 11 G A 0.62 0.237 6.60E-13 0.0001 0.62 0.228 4.30E-13 0.0002 
rs113443718 16 G A 0.69 0.251 9.80E-13 0.0001 0.69 0.192 1.90E-08 0.0001 
rs378421 16 G A 0.58 0.228 1.40E-12 0.0001 0.58 0.181 2.00E-08 0.0001 
rs838145 19 G A 0.46 0.229 2.60E-12 0.0001 0.46 0.216 4.70E-12 0.0002 
rs6969458 7 G A 0.53 -0.227 5.00E-12 0.0001 0.53 -0.182 6.40E-09 0.0001 
rs75199129 2 A T 0.95 0.510 1.00E-11 0.0001 0.95 0.320 7.90E-06 0.0001 
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rs13413953 2 T G 0.64 0.228 1.60E-11 0.0001 0.64 0.168 1.80E-07 0.0001 
rs28929474 14 C T 0.98 0.755 2.30E-11 0.0001 0.98 0.389 4.90E-04 0.0001 
rs4480324 1 A G 0.30 0.239 2.60E-11 0.0001 0.29 0.145 3.80E-05 0.0001 
rs12124523 1 C T 0.89 0.340 2.80E-11 0.0001 0.89 0.178 2.70E-04 0.0001 
rs74424378 9 T G 0.76 0.251 3.40E-11 0.0001 0.76 0.208 1.90E-08 0.0001 
rs77294902 17 G A 0.78 0.252 5.00E-11 0.0001 0.78 0.161 1.50E-05 0.0001 
rs6452788 5 G A 0.76 -0.249 5.20E-11 0.0001 0.76 -0.223 8.20E-10 0.0002 
rs7786376 7 A G 0.72 -0.240 6.30E-11 0.0001 0.72 -0.193 4.90E-08 0.0001 
rs7132908 12 G A 0.62 0.206 1.50E-10 0.0001 0.62 0.119 1.80E-04 0.0001 
rs11860773 16 T C 0.80 0.264 1.60E-10 0.0001 0.80 0.204 1.40E-07 0.0001 
rs4815366 20 G T 0.36 -0.213 1.60E-10 0.0001 0.36 -0.162 5.90E-07 0.0001 
rs2858088 4 A G 0.38 -0.208 3.50E-10 0.0001 0.38 -0.129 5.00E-05 0.0001 
rs2959005 15 C T 0.33 -0.216 4.10E-10 0.0001 0.33 -0.100 2.10E-03 0.0000 
rs9349379 6 A G 0.59 -0.207 4.30E-10 0.0001 0.59 -0.146 4.30E-06 0.0001 
rs748919 11 T C 0.79 0.245 4.60E-10 0.0001 0.79 0.131 4.90E-04 0.0000 
rs113441031 16 C T 0.83 0.266 6.40E-10 0.0001 0.83 0.135 1.40E-03 0.0000 
rs109536 9 G C 0.73 -0.222 6.50E-10 0.0001 0.73 -0.102 2.70E-03 0.0000 
rs2717053 2 G C 0.37 -0.205 8.20E-10 0.0001 0.37 -0.074 2.10E-02 0.0000 
rs35572189 17 G A 0.64 -0.205 8.80E-10 0.0001 0.64 -0.089 5.40E-03 0.0000 
rs2274793 14 C T 0.67 0.210 9.20E-10 0.0001 0.67 0.154 1.70E-06 0.0001 
rs147711594 3 G T 0.98 0.651 9.60E-10 0.0001 0.98 0.416 2.90E-05 0.0001 
rs322764 7 G A 0.44 -0.197 1.00E-09 0.0001 0.44 -0.131 3.70E-05 0.0001 
rs11692435 2 G A 0.92 -0.364 1.10E-09 0.0001 0.92 -0.156 4.80E-03 0.0000 
rs7940127 11 T C 0.14 -0.281 1.10E-09 0.0001 0.14 -0.144 1.30E-03 0.0000 
rs11648570 16 T C 0.89 -0.318 1.30E-09 0.0001 0.89 -0.243 1.80E-06 0.0001 
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rs72726477 4 G A 0.88 0.304 1.30E-09 0.0001 0.88 0.136 4.40E-03 0.0000 
rs75543135 19 T A 0.88 -0.309 1.70E-09 0.0001 0.88 -0.081 8.90E-02 0.0000 
rs56197131 7 G A 0.80 0.239 2.70E-09 0.0001 0.80 0.170 1.20E-05 0.0001 
rs17177078 16 C T 0.94 0.421 3.10E-09 0.0001 0.94 0.297 1.20E-05 0.0001 
rs324012 12 C T 0.55 -0.194 3.20E-09 0.0001 0.55 -0.084 8.40E-03 0.0000 
rs142687608 16 A G 0.98 0.661 7.50E-09 0.0001 0.98 0.508 5.30E-06 0.0001 
rs6136465 20 G A 0.60 0.190 8.00E-09 0.0001 0.60 0.124 6.10E-05 0.0001 
rs7630012 3 A G 0.57 0.186 8.00E-09 0.0001 0.57 0.165 2.00E-07 0.0001 
rs77123275 9 C T 0.95 -0.415 8.10E-09 0.0001 0.95 -0.284 5.70E-05 0.0001 
rs3809162 12 A G 0.59 -0.185 8.30E-09 0.0001 0.59 -0.195 6.40E-10 0.0002 
rs28601761 8 C G 0.58 -0.193 8.40E-09 0.0001 0.58 -0.103 1.60E-03 0.0000 
rs9639559 7 C T 0.28 -0.213 8.40E-09 0.0001 0.27 -0.136 9.70E-05 0.0001 
rs4775792 15 T G 0.37 0.192 8.50E-09 0.0001 0.37 0.094 4.50E-03 0.0000 
rs17446532 9 C T 0.51 -0.182 8.80E-09 0.0001 0.51 -0.106 8.20E-04 0.0000 
rs12899560 15 C T 0.59 -0.195 9.60E-09 0.0001 0.59 -0.096 2.20E-03 0.0000 
rs11773627 7 T C 0.81 -0.238 9.70E-09 0.0001 0.81 -0.093 2.10E-02 0.0000 
rs2117760 3 C A 0.71 0.198 1.00E-08 0.0001 0.71 0.180 1.40E-07 0.0001 
rs7673993 4 A G 0.58 -0.187 1.10E-08 0.0001 0.58 -0.161 3.60E-07 0.0001 
rs142488468 10 G C 0.82 0.238 1.30E-08 0.0001 0.82 0.146 1.90E-04 0.0001 
rs7499750 16 A C 0.22 0.217 1.40E-08 0.0001 0.23 0.170 6.00E-06 0.0001 
rs2584448 4 T G 0.43 -0.187 1.70E-08 0.0001 0.43 -0.159 5.00E-07 0.0001 
rs17884691 22 G A 0.75 0.208 2.00E-08 0.0001 0.75 0.155 2.60E-05 0.0001 
rs756747 7 T G 0.48 -0.183 2.00E-08 0.0001 0.48 -0.111 2.30E-04 0.0001 
rs11030084 11 C T 0.81 0.228 2.20E-08 0.0001 0.81 0.113 3.30E-03 0.0000 
rs1713675 11 A G 0.51 -0.183 2.40E-08 0.0001 0.51 -0.132 4.40E-05 0.0001 
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rs2756185 6 G A 0.93 0.337 2.60E-08 0.0001 0.93 0.066 2.10E-01 0.0000 
rs11079849 17 C T 0.67 -0.195 2.80E-08 0.0001 0.67 -0.111 9.20E-04 0.0000 
rs118784 5 T A 0.50 -0.178 3.20E-08 0.0001 0.50 -0.110 3.30E-04 0.0001 
rs78621285 16 A T 0.91 0.312 3.20E-08 0.0001 0.91 0.175 1.10E-03 0.0000 
rs1788820 18 A G 0.35 -0.186 3.40E-08 0.0001 0.34 -0.156 1.70E-06 0.0001 
rs2068650 5 A C 0.53 0.178 3.70E-08 0.0001 0.53 0.145 2.60E-06 0.0001 
rs6690101 1 T C 0.46 -0.178 3.90E-08 0.0001 0.46 -0.114 2.80E-04 0.0001 
rs1788030 18 C T 0.54 0.179 4.70E-08 0.0001 0.54 0.096 3.00E-03 0.0000 
rs11090045 22 G A 0.69 0.194 4.80E-08 0.0001 0.69 0.129 1.50E-04 0.0001 
Combined       0.0094    0.0095 
 
 
Supplementary Table 4. Power calculation for MR analysis 
Outcome Number of Controls Number of cases OR>1.15 OR>1.20 OR>1.30 
Breast cancer 105974 122977 0.91 0.99 0.99 
Ovarian cancer 40941 22406 0.4 0.62 0.91 
 
Power for MR analysis estimated for a 1SD change in alcohol intake (~1.4 stand drinks/day) using mRnd power 












Supplementary Table 5. Estimated hazard ratios for the association between daily alcohol 
consumption and breast and ovarian cancer in the CCHS+CGPS for different consumption levels. 
Breast cancer Total sample size HR (adjusted model) P-value 
Daily number of drinks (1 drink=12g) 
0.0-0.9 44451 0.91 (0.82, 1.00) 0.05 
1.0-1.9 21435 REF - 
2.0-2.9 8156 1.11 (0.97, 1.27) 0.13 
3.0-3.0 2765 1.24 (1.02, 1.51) 0.03 
4.0-4.9 871 1.38 (1.00, 1.90) 0.05 
5.0-9.9 550 1.36 (0.91, 2.03) 0.13 
>=10 38 4.3 (1.61, 11.49) 0.004 
   P-trend= 0.02 
Ovarian cancer    
Daily number of drinks (1 drink=12g) 
0.0-0.9 45601 1.19 (0.91, 1.55) 0.22 
1.0-1.9 22242 REF  
2.0-2.9 8510 1.19 (0.81, 1.74) 0.37 
3.0-3.0 2873 0.62 (0.29, 1.35) 0.23 
4.0-4.9 916 2.89 (1.50, 5.58) 0.002 
5.0-9.9 566 1.87 (0.69, 5.12) 0.22 
>=10 no events   
   P-trend=0.32 
Analyses used age as the underlying time, and were adjusted for cohort (CCHS or CGPS), birth year, and examination year. For 





Supplementary Table 6. Estimated hazard ratio for the association between daily alcohol drinks with 
breast cancer in the KARMA study for different consumption levels. 
Study Category  
(daily alcohol intake, in grams) 
HR (only age adjusted) HR (full adjusted model) 
KARMA 0.1-9.9g 1.13 (0.93,1.36) 1.10 (0.91,1.34) 
KARMA 10-20g 1.18 (0.79,1.76) 1.14 (0.76,1.69) 
KARMA 20-30g 1.30 (0.62,2.74) 1.25 (0.60,2.64) 
 
 
Supplementary Table 7. Estimated hazard ratio for the association between daily alcohol drinks with 
breast cancer in the KARMA study stratified by ER status of breast cancer. 
Study ER Status Events HR (only age adjusted) HR (full adjusted model) 
KARMA All breast cancer 985 1.09 (0.99,1.20) 1.07 (0.97,1.19) 
KARMA ER+ breast cancer 867 1.10 (0.99,1.23) 1.09 (0.98,1.21) 














Supplementary Table 8. Comparison of age- and fully-adjusted hazard ratios for the association 
between daily alcohol intake and breast and ovarian cancer risk for each study. Age was used as the 
underlying time variable. Participants were censored at the last visit, death or event, whichever came 
first.  
 Only age adjustment Multifactorial adjustment 
Study Events Participants HR_age adjusted Events Participants HR_fully adjusted 
Breast       
KARMA 985 59918 1.12 (1.01,1.24) 985 59918 1.07 (0.97, 1.19) 
CCHS+CGPS 2312 65803 1.07 (1.04, 1.10) 2055 63560 1.09 (1.05, 1.13) 
UK Biobank 4081 141008 1.08 (1.06, 1.10) 1787 64622 1.04 (1.01, 1.07) 
       
Ovarian       
CCHS+CGPS 327 67981 1.05 (0.97, 1.14) 287 62867 1.07 (0.99, 1.16) 
UK Biobank 427 137394 0.97 (0.90, 1.04) 187 61267 0.92 (0.83, 1.03) 
 
The crude HR model is adjusted for recruitment age, top 10 ancestral principal components (UKB only) and Townsend deprivation index (UKB 
only). The adjusted model incorporates the following additional covariates: coffee intake, BMI, height, smoking pack years, menopausal status, 
number of live births, ever smoked, education, duration of moderate and vigorous physical activities and age at menarche. Given that a sizeable 
proportion of the UK Biobank participants are cryptically related, estimates obtained from the UK Biobank had been adjusted for cryptic 














Supplementary Table 9. Comparison of pooled HR estimates obtained through missing covariate data 
imputation against original estimates in the UK Biobank breast and ovarian cancer cohort.  
Outcome Events Participants HR (95% CI) P-value 
Age-adjusted HR model 
Breast cancer 4081 141008 1.08 (1.06, 1.10) 3.20E-15 
Ovarian cancer 427 137394 0.97 (0.90, 1.04) 0.38 
     
Multivariable-adjusted HR model 
Breast cancer 1787 64622 1.04 (1.01, 1.07) 0.01 
Ovarian cancer 187 61267 0.92 (0.83, 1.03) 0.16 
     
Pooled multivariable-adjusted HR model using imputed covariate data 
Breast cancer 4081 141008 1.02 (1.00, 1.03) 8.5E-3 
Ovarian cancer 427 137394 0.94 (0.90, 0.99) 0.01 
 
The crude HR model is adjusted for recruitment age, top 10 ancestral principal components (UKB only) and Townsend deprivation index (UKB 
only). The adjusted model incorporates the following additional covariates: coffee intake, BMI, height, smoking pack years, menopausal status, 
number of live births, ever smoked, education, duration of moderate and vigorous physical activities and age at menarche. The pooled HR 
















Supplementary Table 10. Global test for heterogeneity on MR causal estimates. SNP-outliers are 
detected using the conventional Cochran Q-statistics (with df=1), where SNPs that have a heterogeneity 
score > 3.84 are filtered. The causal estimate derived from the filtered set of SNPs are reported in the 
main analysis. 
Trait Methods 
Before filtering heterogenous SNP-
effects After filtering heterogenous SNP-effects 
nsnps 
cochran Q-





All BrCa IVW(main) 34 82.4 2.53E-06 29 26.6 0.54 
 MR-Egger 34 81.9 1.80E-06 29 26.6 0.49 
        
All EOC IVW(main) 34 73.7 6.19E-05 33 24.3 0.83 
 MR-Egger 34 73.3 4.45E-05 33 22.8 0.86 
        
 
The variant(s) that was dropped after heterogeneity filtering were rs11648570, rs2117760, rs61873510 and 
rs62055546 for the breast cancer MR analysis. The variant that was dropped was rs62055546 for the ovarian 















Supplementary Table 11. Comparison of MR estimates across alternative MR methods before and 
after filtering for SNP-heterogeneity. For MR-Egger(bootstrap), 1000 bootstrap iterations were 
performed to obtain reliable standard errors for the causal estimates. PWM stands for the penalized 
weighted median model. 
Outcome MR-model Before filtering for SNP-
heterogeneity 
  After filtering for SNP-
heterogeneity 
P-value OR L_95CI U_95CI   P-
value 
OR L_95CI U_95CI 
All Breast 
cancers 
MR-Egger 0.96 1.00 0.86 1.17  0.83 0.99 0.90 1.09 
  PWM 0.50 0.97 0.89 1.06  0.51 0.97 0.89 1.06 
  IVW (random 
effect) 
0.53 1.03 0.93 1.14  0.78 0.99 0.93 1.06 
 IVW (fixed 
effect) 
0.31 1.03 0.97 1.10  0.78 0.99 0.93 1.06 
                
All EOC MR-Egger 0.27 0.84 0.62 1.14  0.17 0.86 0.71 1.06 
  PWM 0.07 0.84 0.70 1.01  0.003 0.73 0.59 0.90 
  IVW (random 
effect) 
0.23 0.89 0.73 1.08  0.39 0.95 0.85 1.07 
 IVW (fixed 
effect) 






Supplementary Table 12. Multivariable MR analysis adjusting for the effect on adiposity, smoking 
behaviour and education attainment. Changes in the MVMR estimate before and after filtering out 
SNPs with heterogeneous effect sizes indicate that the unadjusted estimates were largely driven by 
outliers. Estimated OR reflect the change in risk per one SD increase in the risk factors. 
Risk factors Outcome 
Before filtering for heterogenous 
variants 
After filtering for heterogenous 
variants 
nsnp pval OR CI_low CI_upper nsnp pval OR CI_low CI_upper 
Cigarette/day 
Breast 









cancer 34 0.02 1.10 1.02 1.19 30 0.31 1.03 0.97 1.10 
Waist-Hip Ratio 
adjusted for BMI 
Breast 
cancer 34 0.00 0.45 0.29 0.70 30 0.03 0.69 0.49 0.97 
BMI 
Breast 
cancer 34 0.92 1.00 0.93 1.07 30 0.95 1.00 0.95 1.06 
            
Cigarette/day 
Ovarian 









cancer 34 0.03 0.82 0.95 1.00 33 0.65 0.97 0.87 1.09 
Waist-Hip Ratio 
adjusted for BMI 
Ovarian 
cancer 34 0.42 1.53 0.55 4.26 33 0.11 0.59 0.31 1.13 
BMI 
Ovarian 
cancer 4 0.43 0.94 0.79 1.11 33 0.98 1.00 0.91 1.11 
 
The variant(s) that was dropped after heterogeneity filtering were rs11648570, rs2117760, rs61873510 and 
rs62055546 for the breast cancer MR analysis. The variant that was dropped was rs62055546 for the ovarian 
cancer MR analysis. PheWAS analysis reveal that the dropped variant rs62055546 in both the breast and ovarian 






Supplementary Table 13. Comparison of instrument strength across various sets of instrument from 
UK Biobank drinks/week GWAS. The median value (and the interquartile range) for the partial F-





Alcohol intake (combined 
sex) Alcohol intake (females only) 
Number of 
SNPs 77 34 34 
Total r2 0.009 0.006 0.007 
Partial  
F-stat 30.31[26.6 - 37.0] 37.3 [29.3 - 46.3] 22.2 [19.5 - 30.3]  
total F 50 75 41.7 
Description 
Variants identified 
from combined sex 
alcohol GWAS 
Variants identified from 
combined sex GWAS that 
replicate in female only 
GWAS (p<1e-5) 
Variants identified from combined sex 
GWAS that replicate in female only 
GWAS (p<1e-5), using EAF and effect 




















Supplementary Table 14. Evidence of replication of UKBB estimated drinks/week (females only) SNP-
association in the GSCAN drinks/week GWAS summary statistics 
 
SNP CHR NEA EA EAF 
BETA_
GSCAN SE_GSCAN N_GSCAN 
PVALUE_
GSCAN PVAL_UKBB 
rs1260326 2 T C 0.60 0.024 0.002 532340 3.33E-33 4.60E-23 
rs75199129 2 A T 0.04 -0.026 0.005 513023 8.44E-09 7.90E-06 
rs1004787 2 G A 0.58 0.015 0.002 526940 3.31E-15 1.10E-13 
rs13413953 2 T G 0.34 -0.012 0.002 529000 5.35E-09 1.80E-07 
rs7630012 3 A G 0.46 -0.007 0.002 535602 0.000423 2.00E-07 
rs2117760 3 C A 0.28 -0.009 0.002 524866 1.01E-05 1.40E-07 
rs9822731 3 T C 0.22 0.017 0.002 531166 5.03E-14 2.40E-07 
rs11940694 4 A G 0.60 0.028 0.002 527865 3.11E-46 1.40E-26 
rs7673993 4 A G 0.41 0.012 0.002 529073 2.65E-09 3.60E-07 
rs1229984 4 T C 0.95 0.188 0.006 514602 1.60E-203 6.80E-121 
rs1302808 4 C A 0.19 0.024 0.002 516605 1.36E-23 6.50E-16 
rs2584448 4 T G 0.54 0.010 0.002 531331 1.83E-07 5.00E-07 
rs13107325 4 C T 0.07 -0.036 0.004 528164 1.23E-20 6.70E-07 
rs6452788 5 G A 0.27 0.012 0.002 535356 3.58E-07 8.20E-10 
rs2068650 5 A C 0.47 -0.009 0.002 527780 2.38E-06 2.60E-06 
rs9349379 6 A G 0.40 0.009 0.002 526515 4.90E-06 4.30E-06 
rs7786376 7 A G 0.27 0.011 0.002 525890 1.01E-06 4.90E-08 
rs6969458 7 G A 0.46 0.013 0.002 509646 5.20E-11 6.40E-09 
rs74424378 9 T G 0.26 -0.011 0.002 530826 1.72E-06 1.90E-08 
rs61873510 10 G T 0.31 -0.011 0.002 500397 8.83E-08 5.80E-08 
rs11604680 11 A G 0.32 -0.015 0.002 526748 2.87E-12 5.80E-07 
rs4630328 11 G A 0.35 -0.014 0.002 531293 3.80E-12 4.30E-13 
rs485425 11 C G 0.54 0.010 0.002 532602 2.13E-07 3.40E-06 
rs3809162 12 A G 0.41 0.010 0.002 527315 4.61E-07 6.40E-10 
rs2274793 14 C T 0.33 -0.012 0.002 531843 3.15E-09 1.70E-06 
rs7499750 16 A C 0.78 -0.009 0.002 534136 0.000192 6.00E-06 
rs378421 16 G A 0.41 -0.013 0.002 508328 2.26E-11 2.00E-08 
rs113443718 16 G A 0.28 -0.011 0.002 510879 5.26E-08 1.90E-08 
rs142687608 16 A G 0.02 -0.021 0.007 489914 0.00226 5.30E-06 
31 
 
rs11648570 16 T C 0.11 0.019 0.003 526153 3.43E-09 1.80E-06 
rs11860773 16 T C 0.18 -0.015 0.002 515422 8.35E-10 1.40E-07 
rs62055546 17 A C 0.20 -0.020 0.002 529432 3.06E-17 1.10E-11 
rs1788820 18 A G 0.65 0.007 0.002 535226 0.000374 1.70E-06 
rs838145 19 G A 0.58 -0.016 0.002 521587 3.87E-16 4.70E-12 
rs4815366 20 G T 0.67 0.009 0.002 534788 2.70E-06 5.90E-07 
 
 





















Supplementary Table 16. Estimate of the MR-Egger intercept for the MR analysis between alcohol 
intake with breast and ovarian cancer risk. For both cancer outcomes, the MR Egger intercept was not 
significantly different from zero, presenting limited evidence against the presence of directional 
pleiotropy biasing the IVW results. 
Outcome Intercept se(intercept) Pvalue 
lower 95% 
C.I. upper 95% C.I. 
All Breast cancer 0.002 0.003 0.483 -0.004 0.008 
      
All EOC -0.001 0.004 0.752 -0.009 0.006 
32 
 
Supplementary Table 17. Pleiotropy assessment on ADH1B SNP rs1229984 using the online 
Phenoscanner database. Beta refer to the magnitude of association on the traits per effect allele (T), the 
none effect allele for the SNP is C. Note that traits that are directly related to alcohol drinking (e.g. 
alcohol dependence) are excluded. Traits with N_cases being zero are quantitative traits. Only 
association estimates derived from Europeans were included. 
 




0.4447 0.0476 1E-20 + - - - 
Self-reported 
gout 











0.0068 0.0009 6.1E-15 + 337159 3819 333340 
Leg fat mass 
right 
-0.042 0.0066 9.4E-11 - 331293 0 331293 
Systolic blood 
pressure 
-0.052 0.0083 3.3E-10 - 317754 0 317754 
Leg fat mass 
left 




-0.03 0.0052 6.5E-09 - 331296 0 331296 
Whole body 
fat mass 















of the above 







-0.019 0.0036 1.1E-07 - 336683 91033 245650 
Sodium in 
urine 
0.0422 0.008 1.2E-07 + 326831 0 326831 
Arm fat mass 
left 
-0.042 0.008 1.4E-07 - 331164 0 331164 
Body fat 
percentage 
-0.033 0.0063 1.5E-07 - 331117 0 331117 
Arm fat mass 
right 
-0.041 0.008 2.5E-07 - 331226 0 331226 
Trunk fat mass -0.042 0.0083 2.9E-07 - 331093 0 331093 




-0.031 0.0062 7E-07 - 331198 0 331198 
Waist 
circumference 
-0.036 0.0073 8.1E-07 - 336639 0 336639 
Self-reported 
hypertension 










-0.025 0.0051 9.9E-07 - 154702 35840 118862 




-0.03 0.0062 1.8E-06 - 331249 0 331249 
Trunk fat 
percentage 
-0.035 0.0075 3.9E-06 - 331113 0 331113 
 
 
Supplementary Table 18. Pleiotropy assessment on ADH1B SNP rs1229984 using database GeneATLAS. 
Shortlisted traits are risk factors that are potentially associated with breast/ovarian cancer. These 
associations are obtained from the UK Biobank only. The GeneATLAS database is available at 
https://geneatlas.roslin.ed.ac.uk/phewas/) 
 
Trait Variant Eff. 
allele 
beta pvalue MAF 
Psychological/psychiatric problem rs1229984 C -0.001564 0.37201 0.0246 
N95 Menopausal and other 
perimenopausal disorders 
rs1229984 C -0.002943 0.12659 0.0246 
Smoking status rs1229984 C -0.003317 0.42239 0.0246 
Body mass index (BMI) rs1229984 C 0.17162 2.6542e-11 0.0246 






Supplementary Table 19. MR association between standard drink/day alcohol consumption and 
breast cancer risk stratified by ER status. The MR association estimates derived from alternative MR 
models (other than the IVW) were shown altogether. For MR-Egger(bootstrap), 1000 bootstrap 
iterations were performed to obtain reliable standard errors for the causal estimates. PWM stands for 
the penalized weighted median model. The confidence interval of the estimated OR for ER- and ER+ 
breast cancer were largely overlapping and included the null (OR=1), indicating minimal meaningful 
differences with respect to the relationship against alcohol intake.  
Outcome MR-model 
Before filtering for SNP-
heterogeneity 
  




OR L_95CI U_95CI   
P-
value 
OR L_95CI U_95CI 
ER- Breast 
cancers 
MR-Egger 0.52 0.93 0.75 1.15   0.2 0.89 0.75 1.06 








0.71 0.98 0.88 1.09  0.74 0.98 0.88 1.09 
                      
ER+ Breast 
cancers 
MR-Egger 0.64 0.96 0.82 1.12   0.37 0.95 0.85 1.06 













Supplementary Figure 1. Comparison of MR association between estimated one standard drink/day 
and breast cancer and EOC susceptibility using single instrument and multiple instrument approaches. 
Estimates for the multi-instrument analyses were derived from 34 alcohol-associated SNPs as per main 
analysis. LMP refer to Low-malignant potential tumours. 
 
 
Supplementary Figure 2. MR association between estimated one standard drink/day and EOC 
susceptibility based on EOC subtypes. Estimates were derived from 34 alcohol-associated SNPs as per 
main analysis. LMP refer to Low-malignant potential tumours. The serous subtype can further be 




Supplementary Figure 3. Scatter plot and forest plot for the genetic association between alcohol 
drinks/week SNP instruments and risk of breast and ovarian cancers. The slope of the fitted line in the 
scatter plots reflect the MR causal estimates for each MR estimator. The forest plot shows the 
association of a genetically predicted one unit increase in alcohol drinks/week (need to be multiplied by 
7 to obtain drink/day) on log(OR) of the outcome (cancer) risk inferred via each alcohol SNP instrument. 
The panel (a) refer to the plots for overall EOC and (b) refer to the plots for the risk of overall breast 
cancers respectively. The rs62055546 variant was consistently dropped after filtering for SNP-
heterogeneity. 
(a) Overall EOC MR scatter plot and forest plot 
 
 




Supplementary Figure 4. MR Leave-one-out plots for the genetic association between alcohol 
drinks/week SNP instruments and risk of breast and ovarian cancers. The forest plot shows the IVW 
estimate of a genetically predicted one unit increase in alcohol drinks/week (need to be multiplied by 7 
to obtain drink/day) on log(OR) of the outcome (cancer) risk inferred via excluding one alcohol SNP 
instrument at a time. The left and right side of panel (a) refer to the Leave-one-out plot for EOC and (b) 
refer to the plots for overall breast cancer.  
(a) Ovarian cancer 
 





Supplementary Figure 5. Phenotypic correlation between covariates and auxilliary variables used in 
the multiple imputation analysis for the UKB cohort. The figure below shows the magnitude of 
correlation between pairs of traits, with correlations that did not achieve nominal significance (p<0.05) 
left blank. The complete list of variables carried forward into the imputation process can be found in 














Supplementary Figure 6. Indicator matrix on the predictability of covariates with missing data from 
other covariates and auxiliary variables estimated from MiCE. For each row, a positive indicator value 
(value=1) indicates that the trait of the corresponding column can be used to predict the row trait in a 
multiple imputation framework (vice versa, for column on row). The total number of predictors for a 
given trait is hence the sum of values across the row and column corresponding to that trait. We 
manually omit the cancer diagnosis outcome variables (diag_age_C50/C56 and C50/C56), genetic sex 
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